Please wait. We are reconciling your results.
 
Logout

Search:

Diabetes mellitus not Diabetes, Type II; and Phase II and More Here not More Here and Phase II and More Here not More Here
176 Unique records out of 447 total.
Source: INTELEOS [ 175 ] - R&D Insight [ 175 ] - IDdb3 [ 175 ] - ims [ 175 ] - PharmaProjects [ 175 ]
     
Select all Records
Display Results Per Page:
Print this report print  |  Export Report to Excel Export Report to Excel
    1 2 3 4 5 6 7 8 9 10    
Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
View All
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
View All
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
View All
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
View All
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
View All
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
View All
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
View All
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Test1
  • Test2
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Test1
  • Test2
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Test1
  • Test2
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Drug Synonyms | Related Companies | View Summaries
Print this Record print  | Export to Excel Export Report to Excel
Auto Reconciled
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Non-Insulin Dependant disease
Reperfusion Injury
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Highest Phase (2) Originator (2) Mech of Action (5)   Indications (7) Development Status - Indications Variables
  • No Development Supported
  • Phase II
  • No Development Supported
  • Phase II
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Allos Therapeutics
  • NGene Research Labratories
  • Roche Parmaceuticals
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  • Insulin response enhancer
  • ADP ribose polymerase inhibitor
  • Chemoprotectant
  • Enzyme, transferase, ADP ribose polymerase
  • Heat shock protein (HSP) inducer
  
 
Cancer
Chemoprotection
Chemotherapy-induced injuries
Diabetes Mellitus
Metabolic Disease
Nin-Insulin Dependant disease
Reperfusion Injury
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
 
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
Country Phase Company Source
Hungary Phase II NGene Research Laboratories Inteleos
United States Phase III Another Company IDdb3
Country Phase Company Source
United States Phase III Another Company IDdb3
Brazil Phase I Some other Company Integrity
Country Phase Company Source
United States Phase II Another Company IDdb3
Russia Phase II Russian Company R&D Insights
   
Status: System Reconciled *Bold indicates reconciled resource values


Display Results Per Page:
Print this report print  |  Export Report to Excel Export Report to Excel
    1 2 3 4 5 6 7 8 9 10    


© 2009 Elsevier Inc. All rights reserved.
Close
Close

Print Drug Records

Records to Print
Record Type
Current: INTELEOS, R&D Insight, IDdb3, Integrity, PharmaProject

Additional Fields
Print Cancel
Close

Export Drug Records

Records to Export
Record Type
Current: INTELEOS, R&D Insight, IDdb3, Integrity, PharmaProject

Additional Fields
Export Cancel